Appendix 4C & Quarterly Update
Filed with ASX ·
6ix is reading this filing.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- FDA Type C Feedback, HEALEY trial potentially registrational
- Neurizon Announces Partial Redemption of Convertible Notes
- NIH funds Expanded Access Program for NUZ-001 in ALS
- Neurizon Appoints Chief Executive Officer
- Appendix 4E and 2026 Annual Report
Later from Neurizon Therapeutics
- Trading Halt
- Firm commitments to raise A$4.3m and announcement of SPP
- Redemption of all remaining Obsidian convertible notes
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics